PYX 102
Alternative Names: Anti-KLRG1 monoclonal antibody; PYX-102Latest Information Update: 19 Jun 2024
At a glance
- Originator Pyxis Oncology; University of Chicago
- Developer Pyxis Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; C-type lectin antagonists; NK cell lectin-like antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 15 Aug 2022 PYX 102 is available for licensing as of 15 Aug 2022. https://pyxisoncology.com/about/
- 15 Aug 2022 Suspended - Preclinical for Cancer in USA (Parenteral)